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1 Drug description 
Generic/Brand name/ATC code:  
Ipilimumab, MDX-010, MDX-101/ Yervoy (proposed trade name)/not yet 
available 
Developer/Company:  
Bristol-Myers-Squibb and Medarex 
Description:  
Ipilimumab is a fully human monoclonal antibody directed against the cyto-
toxic T-lymphocyte antigen 4 (CTLA-4), an antigen which is expressed on 
T-cells only after activation [1]. CTLA-4 down-regulates T-cell mediated 
immune responses. By blocking this antigen, T-cell suppression is reduced 
and thus an anti-tumour immune response enhanced [2, 3].  
Due to its mode of action, a novel set of side-effects, the so called “immune-
related adverse events” (irAEs) appear to be related to anti-CTLA4 antibod-
ies [4]. These AEs are associated with breaking the tolerance to self-antigens 
and are dose-related, cumulative and schedule dependent [3]. A relationship 
between occurrence of these side-effects and anti-tumour activity is being 
discussed [3, 4]. 
Ipilimumab is administered intravenously. Evidence suggests that multiple 
doses should be preferred over single doses: frequently used regimens in 
phase I/II and phase II studies were induction therapy with either 3mg/kg 
or 10mg/kg every three weeks over 12 weeks, followed by maintenance ther-
apy, mostly 10mg/kg every 12 weeks [3]. 
2 Indication 
Ipilimumab is indicated for the treatment of pre-treated patients with ad-
vanced/ metastatic cutaneous melanoma.  
3 Current regulatory status 
Ipilimumab is currently not approved, neither by the EMA nor by the FDA, 
but has received orphan drug status of both institutions [5]. 
In August 2008, Bristol-Myers Squibb Company announced that the FDA 
has granted priority review for ipilimumab for the treatment of adult pa-
tients with advanced melanoma who have been previously treated [6]. Regu-
latory filings were submitted to both the FDA and the EMA in 2010. At first, 
the FDA announced that the review of the application will be completed in 
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December 2010, but the review deadline has been extended until March 
2011 [7, 8].   
4 Burden of disease 
Melanomas are malignant tumours of melanocytes. Suspicious lesions are 
nevi (i.e. moles or birthmarks) with, for example, variable discoloration, 
growth or development of satellites [9]. Risk factors for developing melano-
mas include prior melanomas, a positive family history and multiple clini-
cally atypical moles/dysplastic nevi. In addition, genetic factors and sun ex-
posure can contribute towards the development of melanomas [10]. To con-
firm the diagnosis of melanoma a biopsy, at best by local excision, should be 
performed [9]. Median age at diagnosis is 59 years [9]. 
Staging of melanomas based on the tumour, node, metastasis (TNM) system 
includes describing the spread, aggressiveness and the size of the tumour. By 
taking into account characteristics like thickness, ulcerations and the mi-
totic rate of the primary tumour, by assessing the spread to regional lymph-
nodes including satellite lesions (tumour cells separated from the primary 
tumour) and in-transit metastases and by evaluating distant metastases, pa-
tients are grouped into four prognostic categories (stage I –IV) [11]. Other 
factors which influence prognosis are gender, age and localisation of the tu-
mour where younger patients, women and patients with tumours on the ex-
tremities have a better prognosis [9]. For patients suffering from stage IV 
disease, sites of metastases and elevated lactate-dehydrogenase (LDH) levels 
are also associated with poor outcomes [10]. If the tumour has spread be-
yond near-by lymph-nodes, it is called advanced or metastatic melanoma 
which corresponds to stage IV disease. Metastases most often occur in the 
skin or in lymph-nodes, or in organs such as the lungs, the liver, the brain 
and in the bones. Staging is also an important factor for the determination of 
the most appropriate treatment [11].  
The majority of patients, about 85%, present with localised disease, corre-
sponding to 5-year survival rates of up to 90%. In about 13% the regional 
lymph nodes are affected at diagnosis, leading to diminished survival rates 
of 20%-70%. About 2%-5% of patients present with distant metastases that 
is stage IV. Long-term survival of all patients with distant metastases is less 
than 10% [10]. Median survival is 6 to 9 months [12]. 
In Austria, the incidence of melanomas is about 15 newly diagnosed cas-
es/100 000 persons per year and is constantly rising [13]. In 2007, overall 
1,100 people were newly diagnosed with malignant melanoma in Austria. Of 
those, about 5% of the tumours were already disseminated, resulting in 
about 60 persons with advanced melanoma per year [14]. 
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5 Current treatment 
Treatment of un-resectable stage III melanoma and of stage IV melanomas 
focuses on symptom palliation, on preventing the tumour to spread, to re-
duce or getting rid of metastases and to maintain or achieve an acceptable 
quality-of-life [10]. Thus, cure is rarely possible [11].  
Generally, metastatic melanoma is difficult to treat, because advanced mela-
nomas are refractory to most standard systemic therapies [9]. Accordingly, 
little consensus on the standard of care exists due to the low levels of activity 
of all available options. Therapy may involve: 
 Surgical excision is the primary treatment for early stage melano-
mas, but is also indicated for metastatic melanoma. Resection 
should be performed for limited metastatic melanoma (i.e. if the 
disease has spread only to one site or only to a limited number of 
sites). If the tumour has spread to multiple sites such as the brain, 
the lungs, gastrointestinal tract or lymph-nodes, surgery may be 
used for symptom palliation.   
 Single-agent chemotherapy:  
 dacarbazine (DTIC)  is currently the most active chemo-
therapy and has often been used as standard comparator 
for new therapeutic regimens [10]. However, only 10%-
20% of patients respond to this treatment, showing mainly 
partial remissions with a median response duration of 3-4 
months [10].  
 fotemustine for the treatment of disseminated malignant 
melanoma, foremost if the tumour has spread to the brain 
[15]. 
 temozolomide (off-label) shows similar benefits like DTIC. 
Due to its ability to penetrate into the brain and other 
parts of the nervous system, it is often used for the treat-
ment of patients with brain metastases [11].  
 Immunotherapy:  
 high-dose interleukin-2 (licensed in the US) has shown 
long-lasting effects including complete remissions, but on-
ly in the minority of patients. Because of its serious side-
effects, it remains a treatment option for patients in good 
condition. 
 interferon-α is licensed for the adjuvant therapy of patients 
who are disease-free after surgery but who are at high risk 
of systemic recurrence [11]. 
 Radiation therapy either to metastases outside the brain for symp-
tom palliation or as whole brain radiation therapy which can pro-
long survival, especially if the tumour outside the brain is con-
trolled [11]. 
 Due to the low effectiveness of the available treatment options, all 
newly diagnosed patients with advanced melanoma should be con-
sidered for participating in clinical trials [9].  
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6 Evidence 
One phase III trial [16], 3 phase II trials [17-19] and one study reporting on 
a compassionate use programme were found [20].  
The phase III trial evaluated ipilimumab either alone or in combination 
with a vaccine in comparison to that vaccine alone in 676 pre-treated pa-
tients with advanced melanoma [16]. With 10 months median overall sur-
vival (OS) was improved significantly for both groups treated with ipilimu-
mab in comparison to 6.4 months for patients treated with the vaccine alone. 
Adverse events were very frequent and 12 (i.e. 2.3%) ipilimumab-related 
deaths were observed. 
Three phase II studies were found which were either single-armed, dose-
ranging studies or had the primary objective of assessing the addition of 
budesonide for the treatment of diarrhoea, an irAE associated with ipilimu-
mab [18, 19, 21]. In addition, results of one study reporting on a compas-
sionate use programme are reported [20]. Best overall response rates 
(BORR) ranged from 6% -16% for 10mg/kg ipilimumab and OS was 7 
months to 19 months. Drug-related adverse events were also observed very 
frequently (in up to 95% of patients). irAEs of any grade were the most 
common adverse events and occurred in 65% - 84% of patients. One study 
mentioned that 5 deaths (i.e. approximately 3%) might have been treatment 
related.  
6.1 Efficacy and safety - Phase III studies 
Table 1.: Summary of efficacy  
Study title:  Improved survival with Ipilimumab in patients with metastatic melanoma [16] 
Study identifier NCT00094653 
Sponsor Bristol-Myers Squibb, Medarex 
Phase III, randomized (3:1:1 ratio), double-blind, multicenter, three-arm, placebo controlled Design 
Duration  Endpoint specific, patients were randomly assigned to study groups 
between September 2004 and August 2008 
 
Hypothesis Superiority 
 
Intervention 1 Ipilimumab 3mg/kg body weight i.v. + gp 100 vaccine s.c 
once every 3 weeks for 4 treatments, 403 patients 
Intervention 2 ipilimumab 3mg/kg body weight i.v. + placebo once every 3 weeks 
for 4 treatments, 137 patients 
Treatment groups 
Control gp100 vaccine s.c. + placebo once every 3 weeks for 4 treatments, 
136 patients 
Overall survival  
 
OS Time from randomization to death from any cause 
Progression-free survival PFS Time from randomization to documented disease 
progression or death 
Best overall response 
rate 
BORR Proportion of patients with a partial or complete re-
sponse 
Endpoints and defini-
tions 
Complete response CR Disappearance of all known disease 
1 phase III trial, 3 phase 
II trials and 1 report on 
compassionate use  
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Partial response PR A 50% or more decrease in the sum of the products of 
the longest diameter and the greatest perpendicular 
diameter of all target lesions compared to baseline, by 
2 observations (not necessarily consecutive) not less 
than 4 weeks apart. There must be no evidence of in-
tercurrent progressive disease between the first 
measurement showing the 50%decrease and the con-
firmatory observation. 
Stable disease SD Neither sufficient decrease to qualify for partial re-
sponse nor sufficient increase to qualify for progres-
sive disease 
Progressive disease PD An increase of 25% or more in the sum of the prod-
ucts of the longest diameter and the greatest perpen-
dicular diameter of target lesions compared to the 
smallest recorded sum (nadir) during the study, or 
appearance of one or more new lesions. A single pro-
gressing lesion that does not raise the overall sum of 
the product of the diameters by 25% will not be con-
sidered progressive disease 
Disease control rate DCR Percentage of patients with a partial or complete re-
sponse or stable disease 
Database lock August 2009 (Final data collection date for primary outcome measure) 
Results and analysis 
Analysis description Primary analysis: Intention-to-treat analysis 
Analysis population  Characteristics: mean age 56 years, LDH ≤ upper limit of the normal range 62%, M0: 2%, 
M1a (= Metastases to distant skin, subcutaneous, or lymph node sites, with a normal serum 
LDH): 9%, M1b (= Lung metastases in patients with a normal serum LDH): 18%, M1c (= 
Metastases to other visceral sites with a normal serum LDH OR any metastasis associated 
with an elevated serum LDH): 71%  
Inclusion: un-resectable stage III or stage IV melanoma, previously treated (DTIC, temo-
zolomide, fotemustine, carboplatin, IL-2), Eastern Cooperative Oncology Group Perform-
ance Status (ECOG PS) 0 or 1, positive status for HLA-A*0201, life expectancy of at least 4 
months 
Exclusion: active, untreated metastases in the central nervous system 
Treatment group Intervention 1 Intervention 2 Control 
Number of subjects 403 137 136 
OS (months) 
Median 
95%CI 
 
10.0 
8.5 to 11.5 
 
10.1 
8.0 to 13.8 
 
6.4 
5.5 to 8.7 
PFS (months) 
Median 
95%CI 
 
2.76 
2.73 to 2.79 
 
2.86 
2.76 to 3.02 
 
2.76 
2.73 to 2.83 
PFS rate at 12 weeks 
(%) 
95% CI 
 
49.1 
44.1 to 53.9 
 
57.7 
48.9 to 65.5 
 
48.5 
39.6 to 56.7 
BORR  
(%) 
95% CI 
 
5.7 
3.7 to 8.4 
 
10.9 
6.3 to 17.4 
 
1.5 
0.2 to 5.2 
CR (%) 0.2 1.5 0 
PR (%) 5.5 9.5 1.5 
SD (%) 14.4 17.5 9.6 
PD (%) 59.3 51.1 65.4 
DCR (%) 
95% CI 
20.1 
16.3 to 24.3 
28.5 
21.1 to 36.8 
11.0 
6.3 to 17.5 
Descriptive statistics 
and estimate variabil-
ity 
OS rates (%) at:  
12 months  
18 months 
24 months 
 
43.6 
30.0 
21.6 
 
45.6 
33.2 
23.5 
 
25.3 
16.3 
13.7 
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Comparison groups Intervention 1 vs Control 
Hazard ratio 0.68 
95% CI 0.55 to 0.85 
P value  <0.001 
Comparison groups Intervention 2 vs Control 
Hazard ratio 0.66 
95% CI 0.51 to 0.87 
P value  0.003 
Comparison groups Intervention 1 vs Intervention 2 
Hazard ratio 1.04 
95% CI 0.83 to 1.30 
OS 
(primary outcome : in-
tervention 1 vs. con-
trol) 
P value  0.76 
Comparison groups Intervention 1 vs Control 
Hazard ratio 0.81 
95% CI NA 
P value  <0.05 
Comparison groups Intervention 2 vs Control 
Hazard ratio 0.64 
95% CI NA 
P value  <0.001 
Comparison groups Intervention 1 vs Intervention 2 
Hazard ratio 1.25 
95% CI NA 
Effect estimate per 
comparison 
PFS 
 
P value 0.04 
Notes • The original primary endpoint was best overall response rate but the primary end-
point was amended to overall survival with the amendment approved in January 2009 
• Re-induction therapy was offered to patients with stable disease of ≥ 3 months 
from week 12 or to patients who achieved a partial or complete response at week 12 
• Patients with progressive disease who were not eligible for continued therapy or 
for re-induction were permitted to receive non-study cancer therapy 
 
Table 2: Most frequent adverse events 
Grade  
(CTC version 3.0) 
Outcome Intervention 1 
(n=380) 
Intervention 2 
(n=131) 
Control 
(n=132) 
All Grades Any event (%) 98.4 96.9 97.0 
 Any drug related event (%) 88.9 80.2 78.8 
 Any immune-related event (%) 58.2 61.1 31.8 
Grade 3 Any event (%) 38.7 37.4 40.9 
 Any drug related event (%) 16.3 19.1 11.4 
 Diarrhea (%) 4.2 5.3 0.8 
 Anaemia (%) 2.9 3.1 8.3 
 Any immune-related event (%) 9.7 12.2 3.0 
 Colitis (irAE)1  (%) 2.9 5.3 0 
Grade 4 Any event (%) 6.8 8.4 6.1 
 Any drug related event (%) 1.1 3.8 0 
 Any immune-related event 0.5 2.3 0 
 Dyspnea (%) 0.5 0.8 0 
 Gastrointestinal (irAE) (%) 0.5 0 0 
Other outcomes Deaths related to study drug (no/%) 8 (2.1) 4 (3.1) 2 (1.5) 
                                                             
1 irAE = immune-related adverse event 
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This phase III study investigated ipilimumab either in combination with gp 
100 or alone in comparison to gp100 alone. Gp100 is an experimental vac-
cine derived from a melanosomal protein comprising HLA-A*0201-
restricted peptides that had previously shown some benefit in melanoma. 
Therefore positive status for HLA-A*0201 was one inclusion criteria. Fur-
ther eligibility criteria were previously treated patients with un-resectable 
stage III or stage IV melanoma and with a good performance status. About 
70% of patients had M1c metastatic disease, defined as metastases to other 
visceral sites with a normal serum LDH or any metastasis associated with an 
elevated serum LDH, a stage associated with a poor prognosis [11].  
Overall 676 patients were allocated in a 3:1:1 ratio to three groups: ipilimu-
mab + gp100, ipilimumab alone and gp100 alone. The initial primary out-
come, best overall response rate, was changed to OS after the study’s start. 
Both groups which had received ipilimumab showed improved outcomes in 
OS. In the ipilimumab + gp100 group median OS was 10 months in com-
parison to 6.4 months for the gp100 only group, resulting in a HR of 0.68 
(p<0.001). When ipilimumab alone (median OS was 10.1 months) was as-
sessed in comparison to gp100 alone, HR was 0.66 (p=0.003). No differences 
were found between the two ipilimumab groups. In a subgroup analysis, the-
se effects appeared to be independent of gender, age, metastasis stage of dis-
ease, and prior interleukin-2 treatment. Median progression-free survival 
(PFS) was similar for all groups at 12 weeks; afterwards, however, differ-
ences occurred in the risk of progression between patients treated with 
ipilimumab and those treated with gp100.  
With approximately 11%, the highest best overall response rate (BORR), de-
fined as patients with either partial or complete response, was found in the 
ipilimumab alone group. An objective response for at least 2 years was main-
tained in 9 of 15 patients (60%) in the ipilimumab alone group and in 4 of 
23 patients (17%) in the ipilimumab+gp100 group. 2 patients in the vaccine 
only group had a partial response, but none of them maintained the re-
sponse for 2 years.  
Of the 31 patients who received re-induction therapy with ipilimumab, 1 pa-
tient showed a complete response, 5 a partial response and the remaining 15 
patients had stable disease.  
Adverse events were very frequent in each group. Drug related events of any 
grade were observed in 89% of patients in the ipilimumab+gp100 group, in 
80% of the ipilimumab alone group and in 79% of the gp100 alone group. 
IrAEs, defined as AEs associated with exposure to the study drug and consis-
tent with an immune phenomenon, occurred in about 60% of patients 
treated with ipilimumab, whereas 32% of the gp100 only group experienced 
these side-effects. For irAEs of grade ≥2 to resolve, it took about 6 weeks in 
the ipilimumab + gp100 group, 5 weeks for the ipilimumab only group and 
3 weeks for the gp100 alone group. In total, 14 deaths related to the study 
drugs were observed out of which 12 occurred in patients treated with 
ipilimumab (2.3%). 
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6.2 Efficacy and safety - further studies 
A single-arm phase II study [17] evaluated induction therapy (every 3 
weeks) followed by maintenance therapy (every 3 months) with 10mg/kg 
ipilimumab in 155 previously treated patients with un-resectable stage 
III/IV melanoma. The BORR, the primary outcome of this study, was 5.8% 
At a median follow-up time of 10 months, median OS was 10.2 months (95% 
CI 7.6-16.3); the 12 months, 18 months and 24 months survival rates were 
47.2%, 39.4% and 32.8% respectively - follow-up is still on-going. Drug-
related adverse events were observed in 84% of patients. 54% of patients ex-
perienced serious adverse events where 32% were considered drug related. 
irAEs of any grade were the most frequent adverse events and occurred in 
70% of patients. 5 deaths might have been treatment related.  
A phase II dose-ranging study conducted by Wolchok et al. [18] comprised 
213 previously treated with stage III/IV melanoma. Three different dosing 
regimens (0.3 mg/kg; 3mg/kg; 10mg/kg) were administered for induction 
therapy, followed by maintenance therapy every three months. The highest 
BORR (11.1%) was found for the group with 10mg/kg ipilimumab therapy, 
followed by 4.2% for the 3mg/kg group and 0% for the 0.3mg/kg study arm. 
Median OS was 11.4 (95% CI 6.9 - 16.1) months in the 10mg/kg group, 
whereas for the two other groups it was about 8.6 months (95% CI 6.9-12.1 
and 7.7-12.7 for the 3mg/kg and the 0.3mg/kg groups, respectively). irAEs of 
any grade, again the most frequent AEs, increased with the dose applied and 
were seen in 70% of patients in the 10mg/kg group, in 65% in the 3mg/kg 
group and in 26% of the 0.3mg/kg group. No serious irAEs were reported in 
the 0.3mg/kg dose, but in the 10mg/kg group the most frequent irAEs of 
grade 3 or 4 were gastrointestinal (15%) and dermatologic (4%) ones.  
Another phase II study had the primary objective of assessing the rates of 
grade ≥2 diarrhoea, an irAE associated with ipilimumab, if ipilimumab was 
administered at 10mg/kg either alone or in combination with prophylactic 
budesonide [19]. No advantages for the prophylactic administration of 
budesonide were shown in a total of 115 patients. BORR ranged from 12.1% 
to 15.8%; 1 year survival rates were 55.9% (95% CI 42.7-68.6) to 62.4% (95% 
CI 49.4-75.1) and the median OS was 17.7 months and 19.3 months. Any 
drug-related events were very frequently observed (90% in the combination 
arm, 95% in the ipilimumab only arm) as well were irAEs of any grade (81% 
in the combination arm, 84% in the ipilimumab only arm). The incidence of 
higher grade irAEs was about 40%, with 28% attributable to grade 3 and 
12% attributable to grade 4% events.  
Ku et al. [20] report results of 51 patients with advanced refractory mela-
noma which were treated with 10mg/kg ipilimumab in an compassionate 
use setting. Median PFS was 2.6 months (95% CI 2.3-5.2 months) and me-
dian OS was 7.2 months (95% CI 4.0-13.3 months). Objective response rate 
was 12% (95% CI 5%-25%). In terms of side-effects, no treatment-related 
deaths were observed, but irAEs of grade 3 or 4 were seen in 29% of patients. 
The most common grade 3 AEs included diarrhoea (16%), lymphopenia 
(18%), dyspnoea, anaemia and fatigue (each 8%). Elevations of the liver en-
zymes and infections (each 4%) were the most common grade 4 AEs.  
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7 Estimated costs 
The costs of ipilimumab have not been determined yet. In the investigated 
indication, it is clear that the expenses will occur in addition to prior thera-
pies and costs for the treatment of side-effects. Nonetheless, as long as ipili-
mumab will be used for the treatment of advanced/metastatic melanoma on-
ly, the overall costs will be kept within a limit due to the limited number of 
eligible patients.  
8 On-going research 
NCT00162123: evaluates the continued use of ipilimumab in patients who 
had clinical benefit in a prior/parent study and are now eligible to receive 
either re-Induction at the time of disease progression or to continue mainte-
nance treatment. The planned end is March 2011.  
NCT00324155: compares ipilimumab + DTIC to DTIC alone in untreated 
patients with un-resectable stage III or IV melanoma. The trial is on-going 
but not recruiting anymore. Final data collection date is November 2010 and 
the expected end of the study is November 2011.  
NCT00636168 is currently recruiting patients and assesses ipilimumab ver-
sus placebo to prevent recurrence after complete resection of high risk stage 
III melanoma. The study will be completed in September 2014.  
In addition, two phase III studies are recruiting patients to evaluate ipili-
mumab for the treatment of prostate cancer.  
Plenty phase I or phase II studies for melanoma were found, including vari-
ous combinations (e.g. temozolomide, bevacizumab, sargramostim). Besides 
melanoma, other indications under investigation are prostate cancer, non-
small cell lung cancer, breast cancer and pancreatic cancer. 
9 Commentary  
Ipilimumab for pre-treated patients with un-resectable stage III or stage IV 
melanomas has not been approved yet, neither by the FDA nor by the EMA. 
The FDA has announced that first decisions on market approval will be re-
leased in March 2011.  
Marketing authorization is sought mainly based on a phase III trial which 
evaluated ipilimumab either alone or in combination with gp100, an ex-
perimental vaccine, in comparison to that vaccine alone [16]. 676 previously 
treated patients suffering from un-resectable stage III or stage IV melanoma 
were included. The primary outcome had initially been best overall response 
rate, but was changed to OS during the study. Median OS in comparison to 
gp100 alone was prolonged by 3.6 and 3.7 months in the groups treated with 
ipilimumab. Improvements were also found for other outcomes such as PFS, 
costs unknown  
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where the risk of progression was diminished by 19% with ipilimumab + 
gp100 in comparison to gp100 alone, and by 36% with ipilimumab alone as 
compared to gp100 alone. The addition of gp100 to ipilimumab did not re-
sult in better outcomes than ipilimumab alone.  
Adverse events were very frequent. The most common ones were irAEs (im-
mune-related adverse events due to the immune-based mode of action of 
ipilimumab), which occurred in about 60% of patients treated with ipili-
mumab and in 32% of the gp100 group. Treatment related deaths were ob-
served in about 2% of patients treated with ipilimumab.  
In addition, three phase II studies and one study on a compassionate use 
programme [18-21] reported best overall response rates ranging from 6% -
16% for 10mg/kg ipilimumab and OS of 7 months to 19 months. Drug-
related adverse events were also observed very frequently (in up to 95% of 
patients). irAEs of any grade were the most common adverse events and oc-
curred in 65% - 84% of patients. One study mentioned that 5 deaths (i.e. ap-
proximately 3%) might have been treatment related.  
Therapy of advanced melanomas proves very difficult as only few agents are 
licensed in Europe and treatment options in general show only limited activ-
ity, resulting in a median survival of 6 to 9 months. Against this background 
even a prolongation of OS by more than 3 months can be called a success, 
especially since ipilimumab is the first therapy which demonstrated im-
provements in OS in pre-treated advanced melanoma [3].  
Despite these findings, many open questions concerning ipilimumab ther-
apy remain. For one, it can be questioned whether choosing another experi-
mental therapy (i.e.gp100) as comparator was reasonable or if delivering 
“best supportive care” to the control group would not have provided more 
meaningful results. Also, data on quality-of-life are missing but would be in 
the light of high rates of sometimes serious and life-threatening adverse 
events of utmost interest. Moreover, as the BORR (i.e. proportion of patients 
with partial or complete response) was 11%, only the minority of patients 
seem to respond to ipilimumab therapy [22]. Hence, markers are needed 
which allow to predict response to this treatment [3] and thus to spare pa-
tients, which are unlikely to respond, severe side-effects.  
Other unresolved issues concern the optimal dosing and duration of ipili-
mumab therapy. For example, the dose (i.e. 3mg/kg), administered in the 
above mentioned phase III trial, was in comparison to other trials relatively 
low. Regarding the optimal treatment duration, some authors argue that new 
response criteria are necessary for immunotherapeutic agents such as ipili-
mumab, because response can occur even after an initial increase in tumour 
burden or after the development of new lesions. According to the standard 
response criteria, this response would be labelled as “progressive disease” 
and would therefore lead to the termination of ipilimumab therapy [3, 23, 
24]. However, as these new criteria have not been evaluated, applying them 
wrongly might result in the very opposite effect, as patients would be ex-
posed for a prolonged period of time to an ineffective, if not toxic therapy 
[25].    
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Other questions which need to be addressed in future clinical trials are if 
ipilimumab should be used as single agent or as combination therapy, as 1st 
or as 2nd-line therapy or how ipilimumab therapy compares to other avail-
able treatment options. Some of these questions might be answered by the 
results of an on-going trial which compares 1st -line ipilimumab with dacara-
bazine (end of study November 2011). 
Even though the price of ipilimumab has not been determined, due to its 
orphan drug status and the rather limited treatment options for advanced 
melanoma, it might be sold at high prices – if licensed in the first place. Be-
cause of the limited number of patients with pre-treated advanced melano-
mas, even a high price will not have major implications for health care ser-
vices. But since ipilimumab is under investigation for other types of cancers, 
including very frequent ones such as lung-cancer, pricing of ipilimumab 
might become important in the future. 
Therapeutic options for advanced/metastatic melanoma are limited. If the 
EMA grants market authorization for ipilimumab, a treatment option for 
this difficult to treat disease will become available for which increases in OS 
have been demonstrated. However, this therapy is associated with sometimes 
severe and life-threatening adverse events and many unresolved questions 
still remain.   
 
as single agent or 
combination therapy? 
1st line or 2nd line 
therapy? 
 
costs? 
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